vs
AC Immune SA（ACIU）与Alpha Cognition Inc.（ACOG）财务数据对比。点击上方公司名可切换其他公司
Alpha Cognition Inc.的季度营收约是AC Immune SA的1.9倍（$2.8M vs $1.4M）。Alpha Cognition Inc.净利率更高（-245.5% vs -1622.4%，领先1377.0%）
AC Immune SA是一家临床阶段生物制药企业，专注于开发阿尔茨海默病、帕金森病及罕见tau蛋白病等神经退行性疾病的创新疗法与诊断方案，与全球领先药企展开合作，致力于满足神经疾病领域未被满足的临床需求。
ACIU vs ACOG — 直观对比
营收规模更大
ACOG
是对方的1.9倍
$1.4M
净利率更高
ACOG
高出1377.0%
-1622.4%
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4M | $2.8M |
| 净利润 | $-23.3M | $-6.9M |
| 毛利率 | — | — |
| 营业利润率 | -1484.5% | -283.7% |
| 净利率 | -1622.4% | -245.5% |
| 营收同比 | 90.1% | — |
| 净利润同比 | 6.9% | — |
| 每股收益（稀释后） | — | $-0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACIUACOG
| Q4 25 | — | $2.8M | ||
| Q3 25 | — | $2.8M | ||
| Q2 25 | $1.4M | $1.7M | ||
| Q1 25 | — | $2.9M | ||
| Q2 24 | $755.7K | — | ||
| Q3 22 | $4.3M | — |
净利润ACIUACOG
| Q4 25 | — | $-6.9M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | $-23.3M | $-10.5M | ||
| Q1 25 | — | $-2.0M | ||
| Q2 24 | $-25.0M | — | ||
| Q3 22 | $-14.9M | — |
毛利率ACIUACOG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 96.7% | ||
| Q1 25 | — | 99.6% | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
营业利润率ACIUACOG
| Q4 25 | — | -283.7% | ||
| Q3 25 | — | -187.0% | ||
| Q2 25 | -1484.5% | -346.1% | ||
| Q1 25 | — | -125.9% | ||
| Q2 24 | -3051.1% | — | ||
| Q3 22 | -342.2% | — |
净利率ACIUACOG
| Q4 25 | — | -245.5% | ||
| Q3 25 | — | -46.4% | ||
| Q2 25 | -1622.4% | -632.7% | ||
| Q1 25 | — | -68.5% | ||
| Q2 24 | -3313.0% | — | ||
| Q3 22 | -343.6% | — |
每股收益（稀释后）ACIUACOG
| Q4 25 | — | $-0.10 | ||
| Q3 25 | — | $-0.30 | ||
| Q2 25 | — | $-0.65 | ||
| Q1 25 | — | $-0.13 | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.3M | $66.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $82.2M | $62.5M |
| 总资产 | $209.2M | $79.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACIUACOG
| Q4 25 | — | $66.0M | ||
| Q3 25 | — | $35.4M | ||
| Q2 25 | $28.3M | $39.4M | ||
| Q1 25 | — | $45.5M | ||
| Q2 24 | $56.7M | — | ||
| Q3 22 | $49.0M | — |
股东权益ACIUACOG
| Q4 25 | — | $62.5M | ||
| Q3 25 | — | $33.9M | ||
| Q2 25 | $82.2M | $31.9M | ||
| Q1 25 | — | $40.8M | ||
| Q2 24 | $135.8M | — | ||
| Q3 22 | $209.1M | — |
总资产ACIUACOG
| Q4 25 | — | $79.7M | ||
| Q3 25 | — | $46.3M | ||
| Q2 25 | $209.2M | $45.1M | ||
| Q1 25 | — | $48.6M | ||
| Q2 24 | $261.3M | — | ||
| Q3 22 | $226.1M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-6.9M |
| 自由现金流经营现金流 - 资本支出 | — | $-7.1M |
| 自由现金流率自由现金流/营收 | — | -252.6% |
| 资本支出强度资本支出/营收 | — | 5.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-20.7M |
8季度趋势，按日历期对齐
经营现金流ACIUACOG
| Q4 25 | — | $-6.9M | ||
| Q3 25 | — | $-5.3M | ||
| Q2 25 | — | $-6.1M | ||
| Q1 25 | — | $-2.0M | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
自由现金流ACIUACOG
| Q4 25 | — | $-7.1M | ||
| Q3 25 | — | $-5.4M | ||
| Q2 25 | — | $-6.1M | ||
| Q1 25 | — | $-2.1M | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
自由现金流率ACIUACOG
| Q4 25 | — | -252.6% | ||
| Q3 25 | — | -188.8% | ||
| Q2 25 | — | -370.9% | ||
| Q1 25 | — | -72.0% | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
资本支出强度ACIUACOG
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 2.2% | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
